Spleen tyrosine kinase suppresses osteoblastic differentiation through MAPK and PKCα

Biochemical and Biophysical Research Communications

Volumn 411, Issue 4, 2011, Pages 774-779

  Yoshida, Kiyoshi ^a   Higuchi, Chikahisa ^a   Nakura, Akio ^a   Yoshikawa, Hideki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

MAPK; MC3T3 E1 cells; Osteoblastic differentiation; PKC ; Spleen tyrosine kinase (Syk)

Indexed keywords

ALP PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C ALPHA; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; PROTEIN TYROSINE KINASE; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; MINERALIZATION; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; WESTERN BLOTTING;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; GENE KNOCKDOWN TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OSTEOBLASTS; OSTEOGENESIS; PROTEIN KINASE C-ALPHA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; STROMAL CELLS;

EID: 80051574624     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.07.023     Document Type: Article

References (29)

1. Taniguchi T., Kobayashi T., Kondo J., Takahashi K., Nakamura H., Suzuki J., Nagai K., Yamada T., Nakamura S., Yamamura H. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. Journal of Biological Chemistry 1991, 266:15790-15796.
2. Kurosaki T., Takata M., Yamanashi Y., Inazu T., Taniguchi T., Yamamoto T., Yamamura H. Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling. Journal of Experimental Medicine 1994, 179:1725-1729.
3. syk expressed in hematopoietic cells. Cellular Signalling 1995, 3:185-193.
4. Cheng A.M., Rowley B., Pao W., Hayday A., Bolen J.B., Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 1995, 378:303-306.
5. Turner M., Mee P.J., Costello P.S., Williams O., Price A.A., Duddy L.P., Furlong M.T., Geahlen R.L., Tyblewicz V.L. Nature 1995, 378:298-302.
6. Sada K., Takano T., Yanagi S., Yamamura H. Structure and function of Syk protein-tyrosine kinase. Journal of Biochemistry 2001, 130:177-186.
7. Koretzky G.A., Abtahian F., Silverman M.A. SLP76 and SLP65: complex regurelation of signaling in lymphocytes and beyond. Nature Review 2006, 6:67-78.
8. Schymeinsky J., Sindrilaru A., Frommhodl D., Sperandio M., Gerstl T., Then C., Mócsai A., Scharffetter-Kochanek K., Walzog B. The Vav biding site of the non-receptor tyrosine kinase Syk at Try 348 is critical for beta2 integrin (CD11/CD18)-mediated neutrophil migration. Blood 2006, 108:3919-3927.
9. Johmura S., Oh-hara M., Inabe K., Nishikawa Y., Hayashi K., Vigorito E., Kitamura D., Turner M., Shingu K., Hikida M., Kurosaki T. Regulation fo VAV localization in membrane rafts by adapter molecules Grb2 ad BLNK. Immunity 2003, 18:777-787.
10. T. Kurosaki, S.A. Johnson, L. Pao, K. Sada, H. Yamamura, J.C. Cambier, Role of the Syk autophosphorylation site and SH2 domains in B cell atigen receptor signaling, Journal of Experimental Medicine 1995 182 1815-1823.
11. Kiefer F., Brumell J., Al-Alawi N., Latour S., Cheng A., Veillete A., Grinstein S., Pawson T. The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutrophils. Molecular and Cellular Biology 1998, 18:4209-4220.
12. Crowley M.T., Costello P.S., Fitzer-Attas C.J., Turner M., Meng F., Lowell C.A., Tybulewicz V.L., DeFranco A.L. A critical role of Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages. The Journal of experimental medicine 1997, 186:1027-1039.
13. Paloneva J., Kestilä M., Wu J., Salminen A., Böhling T., Ruotsalainen V., Hakola P., Bakker A.B., Phillips J.H., Pekkarinen P., Lanier L.L., Timonen T., Peltonen L. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nature Genetics 2000, 25:357-361.
14. Kaifu T., Nakahara J., Inui M., Mishima K., Momiyama T., Kaiji M., Sugahara A., Koito H., Ujike-Asai A., Nakamura A., Kanazawa K., Tan-Takeuchi K., Iwasaki K., Yokoyama W.M., Kudo A., Fujiwara M., Asou H., Takai T. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. Journal of Clinical Investigation 2003, 111:323-332.
15. Humphrey M.B., Ogasawara K., Yao W., Spusta S.C., Daws M.R., Lane N.E., Lanier L.L., Nakamura M.C. The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. Journal of Bone and Mineral Research 2004, 19:224-234.
16. Mósai A., Humphrey M.B., Van Ziffle J.A., Hu Y., Burghardt A., Spusta S.C., Majumdar S., Lanier L.L., Lowell C.A., Nakamura M.C. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (Fc-Rgamma) regulate development of functional osteoclast thorough the Syk tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:6158-6163.
17. Koga T., Inui M., Inoue K., Kim S., Suematsu A., Kobayashi E., Iwata T., Ohnishi H., Matozaki T., Kodama T., Taniguchi T., Takayanagi H., Takai T. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone hemeostasis. Nature 2004, 428:758-763.
18. Zou W., Kitaura H., Reeve J., Long F., Tybulewicz V.L.J., Shattil S.J., Ginsberg M.H., Ross F.P., Teitelbaum S.L. Syk, c-Src, the αvβ3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. Journal of Cell Biology 2007, 176:877-888.
19. Faccio R., Zou W., Colaianni G., Teitelbaum S.L., Ross P. High dose M-CSF partially rescues the Dap12-/- osteoclast phenotype. Journal of Cellular Biochemistry 2003, 90:871-883.
20. Highchi C., Myoui A., Hashimoto N., Kuriyama K., Yoshida K., Yoshidakawa H., Itou K. Continuous inhibiton of MAPK signalling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. Journal of Bone and Mineral Research 2002, 17:1785-1794.
21. Nakura A., Highchi C., Yoshida K., Yoshikawa H. PKCα suppresses osteoblastic differentiation. Bone 2011, 48:476-481.
22. Mósai A., Ruland J., Tybulewicz V.L.J. The Syk tyrosine kinase: a crusial player in diverse biological functions. Nature Review. Immunology 2010, 10:387-402.
23. Gallea S., Lallemand F., Atfi A., Rawadai G., Ramez V., Spinella-Jaegele S., Kawai S., Faucheu C., Huet L., Baron R., Roman-Roman S. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2 induced osteoblast differentiation in pluripotent C2C12 cells. Bone 2001, 28:491-498.
24. Suzuki A., Guicheux J., Palmer G., Miura Y., Oiso Y., Bonjour J.P., Caverzasio J. Exidence for a role of p38 MAP Kinase in expression of alkaline phosphatse during osteoblastic cell differentiation. Bone 2002, 30:91-98.
25. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 1984, 308:693-698.
26. Nishizuka Y. Turnover of inositol phospholipids and signal transduction. Science 1984, 225:1365-1370.
27. Keenan C., Kelleher D. Protein kinase C and the cytoskeleton. Cellular Signalling 1998, 10:225-232.
28. Bajpai M. Fostamitinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs 2009, 12:174-185.
29. Lin Y.C., Huang D.Y., Chu C.L., Lin W.W. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibitor of toll-like receptors-mediated JNK signaling pathway. Molecular Immunology 2010, 47:1569-1578.